Inter Partes Review: Patent Killer No More?

Feng-Chi Chen; Pin-Shen Lee

doi:10.1016/j.tibtech.2019.02.006

Inter Partes Review: Patent Killer No More?

Trends Biotechnol. 2019 Jul;37(7):680-683. doi: 10.1016/j.tibtech.2019.02.006. Epub 2019 Mar 16.

Authors

Feng-Chi Chen¹, Pin-Shen Lee²

Affiliations

¹ Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan; School of Law, National Chiao Tung University, Hsinchu, Taiwan; School of Dentistry, China Medical University, Taichung, Taiwan. Electronic address: fcchen@nhri.org.tw.
² School of Law, National Chiao Tung University, Hsinchu, Taiwan; School of Law, Duke University, Durham, NC, USA.

PMID: 30890272
DOI: 10.1016/j.tibtech.2019.02.006

Abstract

Inter Partes review (IPR) can efficiently invalidate drug patents and potentially convey strategic advantages to follow-on drug makers. However, recent changes in the IPR system foretell a tectonic shift in the landscape. Here we summarize these major changes and discuss the implications for the biopharmaceutical community.

Keywords: Biologics Price Competition and Innovation Act; Hatch-Waxman Act; Inter partes review; patent infringement.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Biological Products / pharmacology*
Biotechnology / legislation & jurisprudence*
Biotechnology / methods*
Drug Industry / legislation & jurisprudence*
Drug Industry / methods*
Humans
Patents as Topic / legislation & jurisprudence*

Substances

Biological Products